US2671750A
(en)
|
1950-09-19 |
1954-03-09 |
Merck & Co Inc |
Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same
|
US3604011A
(en)
|
1968-08-05 |
1971-09-07 |
Rohr Corp |
Turret-type large aperture antenna precision mounted on circular track
|
DE3013839A1
(de)
|
1979-04-13 |
1980-10-30 |
Freunt Ind Co Ltd |
Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
|
US4826689A
(en)
|
1984-05-21 |
1989-05-02 |
University Of Rochester |
Method for making uniformly sized particles from water-insoluble organic compounds
|
CA1282405C
(en)
|
1984-05-21 |
1991-04-02 |
Michael R. Violante |
Method for making uniformly sized particles from water-insoluble organic compounds
|
US4783484A
(en)
|
1984-10-05 |
1988-11-08 |
University Of Rochester |
Particulate composition and use thereof as antimicrobial agent
|
US5340590A
(en)
|
1987-06-25 |
1994-08-23 |
Alza Corporation |
Delivery system with bilayer osmotic engine
|
US5391381A
(en)
|
1987-06-25 |
1995-02-21 |
Alza Corporation |
Dispenser capable of delivering plurality of drug units
|
ATE71032T1
(de)
|
1987-11-17 |
1992-01-15 |
Bosch Gmbh Robert |
Verfahren zur korrektur der durch radsensoren ermittelten drehgeschwindigkeit von fahrzeugraedern.
|
US5133974A
(en)
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
DK469989D0
(da)
|
1989-09-22 |
1989-09-22 |
Bukh Meditec |
Farmaceutisk praeparat
|
DK546289D0
(da)
|
1989-11-02 |
1989-11-02 |
Danochemo As |
Carotenoidpulvere
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
US5201756A
(en)
|
1990-06-20 |
1993-04-13 |
Danforth Biomedical, Inc. |
Radially-expandable tubular elements for use in the construction of medical devices
|
US5399363A
(en)
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
MX9201782A
(es)
|
1991-04-19 |
1992-10-01 |
Sandoz Ag |
Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
|
JPH06511481A
(ja)
|
1991-07-05 |
1994-12-22 |
ユニバーシティ オブ ロチェスター |
気泡を取り込む超微小非凝集多孔質粒子
|
US5223265A
(en)
|
1992-01-10 |
1993-06-29 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery
|
US5209746A
(en)
|
1992-02-18 |
1993-05-11 |
Alza Corporation |
Osmotically driven delivery devices with pulsatile effect
|
US5308348A
(en)
|
1992-02-18 |
1994-05-03 |
Alza Corporation |
Delivery devices with pulsatile effect
|
US5456679A
(en)
|
1992-02-18 |
1995-10-10 |
Alza Corporation |
Delivery devices with pulsatile effect
|
US5221278A
(en)
|
1992-03-12 |
1993-06-22 |
Alza Corporation |
Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
|
US5260068A
(en)
|
1992-05-04 |
1993-11-09 |
Anda Sr Pharmaceuticals Inc. |
Multiparticulate pulsatile drug delivery system
|
US5356476A
(en)
|
1992-06-15 |
1994-10-18 |
Materials Research Corporation |
Semiconductor wafer processing method and apparatus with heat and gas flow control
|
AU660852B2
(en)
|
1992-11-25 |
1995-07-06 |
Elan Pharma International Limited |
Method of grinding pharmaceutical substances
|
US5260069A
(en)
|
1992-11-27 |
1993-11-09 |
Anda Sr Pharmaceuticals Inc. |
Pulsatile particles drug delivery system
|
US5298262A
(en)
|
1992-12-04 |
1994-03-29 |
Sterling Winthrop Inc. |
Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
|
US5346702A
(en)
|
1992-12-04 |
1994-09-13 |
Sterling Winthrop Inc. |
Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
|
US5336507A
(en)
|
1992-12-11 |
1994-08-09 |
Sterling Winthrop Inc. |
Use of charged phospholipids to reduce nanoparticle aggregation
|
US5429824A
(en)
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
US5352459A
(en)
|
1992-12-16 |
1994-10-04 |
Sterling Winthrop Inc. |
Use of purified surface modifiers to prevent particle aggregation during sterilization
|
US6280771B1
(en)
|
1997-02-20 |
2001-08-28 |
Therics, Inc. |
Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
|
DK0752855T3
(da)
|
1994-03-30 |
2000-01-03 |
Gs Dev Ab |
Anvendelse af fedtsyreestere som bioadhæsive substanser
|
US5718388A
(en)
|
1994-05-25 |
1998-02-17 |
Eastman Kodak |
Continuous method of grinding pharmaceutical substances
|
TW384224B
(en)
|
1994-05-25 |
2000-03-11 |
Nano Sys Llc |
Method of preparing submicron particles of a therapeutic or diagnostic agent
|
CA2193806A1
(en)
|
1994-06-22 |
1995-12-28 |
Michael Cardamone |
Controlled release device and method
|
US5556847A
(en)
|
1994-10-27 |
1996-09-17 |
Duquesne University Of The Holy Ghost |
Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
|
US5628981A
(en)
|
1994-12-30 |
1997-05-13 |
Nano Systems L.L.C. |
Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
|
US5665331A
(en)
|
1995-01-10 |
1997-09-09 |
Nanosystems L.L.C. |
Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
|
US5662883A
(en)
|
1995-01-10 |
1997-09-02 |
Nanosystems L.L.C. |
Microprecipitation of micro-nanoparticulate pharmaceutical agents
|
US5560932A
(en)
|
1995-01-10 |
1996-10-01 |
Nano Systems L.L.C. |
Microprecipitation of nanoparticulate pharmaceutical agents
|
US5534270A
(en)
|
1995-02-09 |
1996-07-09 |
Nanosystems Llc |
Method of preparing stable drug nanoparticles
|
US5573783A
(en)
|
1995-02-13 |
1996-11-12 |
Nano Systems L.L.C. |
Redispersible nanoparticulate film matrices with protective overcoats
|
US5510118A
(en)
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
US5543133A
(en)
|
1995-02-14 |
1996-08-06 |
Nanosystems L.L.C. |
Process of preparing x-ray contrast compositions containing nanoparticles
|
EP0810853B1
(en)
|
1995-02-24 |
2004-08-25 |
Elan Pharma International Limited |
Aerosols containing nanoparticle dispersions
|
US5888996A
(en)
|
1995-07-26 |
1999-03-30 |
Trustees Of Boston University |
Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
|
US5629277A
(en)
|
1995-10-04 |
1997-05-13 |
William L. Brown |
Paint removing composition
|
US5840329A
(en)
|
1997-05-15 |
1998-11-24 |
Bioadvances Llc |
Pulsatile drug delivery system
|
GB9711643D0
(en)
|
1997-06-05 |
1997-07-30 |
Janssen Pharmaceutica Nv |
Glass thermoplastic systems
|
AU8145198A
(en)
|
1997-06-16 |
1999-01-04 |
Vertex Pharmaceuticals Incorporated |
Methods of increasing the bioavailability of stable crystal polymorphs of a compound
|
KR20010024453A
(ko)
|
1997-10-08 |
2001-03-26 |
더글라스이.리디치 |
에어로졸 투여용 투약 형태
|
US6607751B1
(en)
|
1997-10-10 |
2003-08-19 |
Intellipharamaceutics Corp. |
Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
|
US5945123A
(en)
|
1998-04-02 |
1999-08-31 |
K-V Pharmaceutical Company |
Maximizing effectiveness of substances used to improve health and well being
|
US8293277B2
(en)
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
NZ511442A
(en)
|
1998-11-02 |
2003-02-28 |
Elan Corp Plc |
Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
|
US6969529B2
(en)
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
US6428814B1
(en)
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
US6039979A
(en)
|
1999-01-13 |
2000-03-21 |
Laboratoires Prographarm |
Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US6267989B1
(en)
|
1999-03-08 |
2001-07-31 |
Klan Pharma International Ltd. |
Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
|
US6423746B1
(en)
|
1999-07-03 |
2002-07-23 |
The William M. Yarbrough Foundation |
Urushiol induced contact dermatitis and method of use
|
WO2001045674A1
(en)
|
1999-12-20 |
2001-06-28 |
Cocensys, Inc. |
Process for producing nanometer particles by fluid bed spray-drying
|
US6689378B1
(en)
|
1999-12-28 |
2004-02-10 |
Kimberly-Clark Worldwide, Inc. |
Cyclodextrins covalently bound to polysaccharides
|
US6627223B2
(en)
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
US6316029B1
(en)
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
US7198795B2
(en)
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US8551526B2
(en)
|
2000-11-03 |
2013-10-08 |
Board Of Regents, The University Of Texas System |
Preparation of drug particles using evaporation precipitation into aqueous solutions
|
US6976647B2
(en)
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
US20030054042A1
(en)
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
DE60222160T2
(de)
|
2001-10-12 |
2008-06-12 |
Elan Pharma International Ltd., Athlone |
Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
|
UA76810C2
(uk)
|
2001-12-10 |
2006-09-15 |
Мерк Енд Ко., Інк. |
Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
|
US20030129242A1
(en)
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
AU2003222027A1
(en)
|
2002-03-20 |
2003-10-08 |
Elan Pharma International Limited |
Fast dissolving dosage forms having reduced friability
|
US20040105889A1
(en)
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
JP2006501148A
(ja)
|
2002-05-03 |
2006-01-12 |
チルドレンズ ホスピタル メディカル センター |
皮膚の清浄化及び他の用途のためのシミュレートされた胎脂組成物
|
JP4776229B2
(ja)
|
2002-07-16 |
2011-09-21 |
エラン ファーマ インターナショナル,リミティド |
安定なナノ粒子活性物質の液体投与組成物
|
EP1542668B1
(en)
|
2002-08-20 |
2009-04-15 |
Bristol-Myers Squibb Company |
Aripiprazole complex formulation and method
|
DK1553927T3
(da)
|
2002-09-11 |
2011-01-31 |
Elan Pharma Int Ltd |
Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
|
CA2510465A1
(en)
|
2002-12-18 |
2004-07-08 |
Pain Therapeutics |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
US20050181050A1
(en)
|
2004-01-28 |
2005-08-18 |
Collegium Pharmaceutical, Inc. |
Dosage forms using drug-loaded ion exchange resins
|
US20050226927A1
(en)
|
2004-04-02 |
2005-10-13 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
|
JP2008505124A
(ja)
|
2004-07-02 |
2008-02-21 |
アドバンシス ファーマスーティカル コーポレイション |
パルス送達用錠剤
|
MX2007011772A
(es)
|
2005-03-23 |
2007-12-05 |
Elan Pharma Int Ltd |
Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas.
|
ES2812250T3
(es)
|
2005-11-28 |
2021-03-16 |
Marinus Pharmaceuticals Inc |
Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
|
BRPI0717721A2
(pt)
|
2006-11-28 |
2013-10-29 |
Marinus Pharmaceuticals |
"partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
|
KR100929920B1
(ko)
|
2007-09-05 |
2009-12-04 |
주식회사 마크로케어 |
사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
|
KR101778603B1
(ko)
|
2009-08-13 |
2017-09-14 |
마리누스 파마슈티컬스 |
3α-히드록시, 3β-메틸-5α-프레그난-20-온 (가낙솔론)의 제조 방법
|
CN102802635B
(zh)
|
2010-01-21 |
2014-07-30 |
吊桥药业有限公司 |
麻醉药制剂
|
EP4245369A3
(en)
|
2011-09-08 |
2023-11-22 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
PT2766380T
(pt)
|
2011-10-14 |
2019-07-29 |
Sage Therapeutics Inc |
Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos
|
PL2806877T3
(pl)
|
2012-01-23 |
2020-06-01 |
Sage Therapeutics, Inc. |
Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
|
US20150175651A1
(en)
|
2012-06-15 |
2015-06-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
MX2015002252A
(es)
|
2012-08-21 |
2015-07-21 |
Sage Therapeutics Inc |
Metodos para tratar epilepsia o estado de epilepsia.
|
CA2892811A1
(en)
|
2012-11-30 |
2014-06-05 |
The Regents Of The University Of California |
Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
|
CN105026415B
(zh)
|
2012-12-18 |
2019-02-01 |
华盛顿大学 |
神经活性的19-烷氧基-17-取代的甾族化合物、其前药以及利用所述化合物的治疗方法
|
EP2956466A4
(en)
|
2013-02-15 |
2016-11-02 |
Univ Washington |
NEUROACTIVE ENANTIOMER STEROLS SUSPENTED AT POSITION 15, 16 AND 17 AS MODULATORS OF TYPE A GABA RECEPTORS
|
US9512170B2
(en)
|
2013-03-01 |
2016-12-06 |
Washington University |
Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
|
RS62235B1
(sr)
|
2013-03-13 |
2021-09-30 |
Sage Therapeutics Inc |
Neuroaktivni steroidi
|
WO2014160441A1
(en)
|
2013-03-13 |
2014-10-02 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
WO2014169833A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
|
WO2014169831A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
|
SI2986624T1
(sl)
|
2013-04-17 |
2020-10-30 |
Sage Therapeutics, Inc. |
19-nor nevroaktivni steroidi za metode zdravljenja
|
WO2014169836A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids and methods of use thereof
|
EP3868382A1
(en)
|
2013-07-19 |
2021-08-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
WO2015081170A2
(en)
|
2013-11-26 |
2015-06-04 |
Systamedic Inc. |
Ganaxolone derivatives for treatment of central nervous systems disorders
|
US9629853B2
(en)
*
|
2014-05-21 |
2017-04-25 |
Wisconsin Alumni Research Foundation |
Uses of ganaxolone
|
EP3149018B1
(en)
|
2014-05-29 |
2020-04-29 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
WO2015187988A1
(en)
*
|
2014-06-04 |
2015-12-10 |
Intellimedix |
Composition and methods of treating epilepsy and/or epilepsy-related disorders
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
EP3253418A1
(en)
|
2015-02-06 |
2017-12-13 |
Marinus Pharmaceuticals, Inc. |
Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
|
EP3632434A1
(en)
*
|
2015-02-25 |
2020-04-08 |
The Regents of the University of California |
The 5ht agonist clemizole for use in treating disorders
|
WO2017066626A1
(en)
|
2015-10-16 |
2017-04-20 |
Marinus Pharmaceuticals, Inc. |
Injectable neurosteroid formulations containing nanoparticles
|
BR112018067998A2
(pt)
*
|
2016-03-08 |
2019-04-16 |
Sage Therapeutics, Inc. |
esteróides neuroativos, composições e usos destes
|
US9996026B2
(en)
|
2016-03-29 |
2018-06-12 |
Canon Kabushiki Kaisha |
Developing apparatus having a large capacity toner storage chamber, and image forming apparatus
|
CN109715151A
(zh)
|
2016-08-11 |
2019-05-03 |
奥维德医疗公司 |
用于治疗癫痫性紊乱的方法和组合物
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
CN110520131A
(zh)
|
2017-04-18 |
2019-11-29 |
马瑞纳斯制药公司 |
缓释可注射的神经类固醇制剂
|
AU2018364659A1
(en)
*
|
2017-11-10 |
2020-05-28 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating genetic epileptic disoders
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|